[Music] Have you ever shared your story online asking for help and it saved your life? I did and 33 people came forward to try donating a kidney. I'm a former amateur boxer. I used to think that I had the courage to go pro. I was I was disciplined. I did everything it took to be that athlete. I thought I knew what courage was until it followed me from the boxing gym to a hospital room. Currently, there are 100,000 people on a kidney transplant weight list. I was one of them. I knew that if I didn't share my ...

Research firm BTI calls this company an emerging leader in a fight against specific types of kidney disease. Millions of people around the world could be candidates for maze therapeutics main drug candidate. Company expects data from its phase 2 trial in the first quarter of next year.They've got a variety though of different programs trying to solve some of these diseases. Jason Col is the CEO of Maze Therapeutics joining us now here in our San Francisco studio for another CNBC exclusive. Jason, good to ha ...

Core Insights - Vivoryon Therapeutics N.V. has reported a transformative year in 2024, successfully shifting its focus towards kidney disease with a viable commercial strategy and strong intellectual property (IP) [3][4] - The company has designed a Phase 2b study for varoglutamstat in diabetic kidney disease (DKD), leveraging statistical evidence from previous studies to maximize the probability of success [4][12] - Financial results indicate a net loss of EUR 20.6 million for 2024, a decrease from EUR 28.3 million in 2023, with cash and cash equivalents of EUR 9.4 million as of December 31, 2024 [30][33] Financial Performance - No revenues were generated in 2024 [27] - Research and development expenses decreased by EUR 3.6 million to EUR 14.1 million, primarily due to lower third-party expenses [28] - General and administrative expenses were EUR 6.9 million, down from EUR 8.6 million in 2023, attributed to lower personnel and legal costs [29] - Cash flows used in operating activities were EUR 19.2 million, compared to EUR 21.5 million in 2023 [31] Strategic Developments - The company has entered into a Standby Equity Purchase Agreement (SEPA) of up to EUR 15 million with Yorkville Advisors, providing financial flexibility for advancing its kidney disease strategy [4][26] - A new varoglutamstat composition of matter patent has been allowed in the U.S., strengthening the company's IP portfolio [4][23] - The management team has been expanded with the addition of Julia Neugebauer as Chief Operating Officer, effective May 1, 2025 [4][26] Clinical Pipeline and Research - Varoglutamstat has shown statistically significant improvement in kidney function (eGFR) in Phase 2 studies, with a notable effect size in diabetic patients [4][12] - The company plans to conduct a Phase 2b clinical study in DKD, targeting approximately 90 subjects with advanced stages of the disease [18] - Pre-clinical data indicates a synergistic effect of varoglutamstat in combination with SGLT2 inhibitors, supporting its potential in treating kidney diseases [21] Future Outlook - Vivoryon expects its cash and cash equivalents to fund operations into January 2026, excluding funds from the SEPA [33][34] - The company aims to confirm previous compelling data from its Phase 2 studies and advance varoglutamstat in kidney disease [18][34] - The identification of a next-generation QPCT/L inhibitor, VY2149, is underway, with plans for late-stage pre-clinical development [20][25]